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Background: Chronic obstructive pulmonary disease (COPD) is associated with increased mortality and poor
health-related quality of life (HRQoL) compared with the general population. The objective of this study was to
identify clinical characteristics which predict mortality and very poor HRQoL among the COPD population and to
develop a Bayesian prediction model.
Methods: The data consisted of 738 patients with COPD who had visited the Pulmonary Clinic of the Helsinki and
Turku University Hospitals during 1995–2006. The data set contained 49 potential predictor variables and two
outcome variables: survival (dead/alive) and HRQoL measured with a 15D instrument (very poor HRQoL < 0.70 vs.
typical HRQoL ≥ 0.70).
In the first phase of model validation we randomly divided the material into a training set (n = 538), and a test set
(n = 200). This procedure was repeated ten times in random fashion to obtain independently created training sets
and corresponding test sets. Modeling was performed by using the training set, and each model was tested by
using the corresponding test set, repeated in each training set. In the second phase the final model was created by
using the total material and eighteen most predictive variables. The performance of six logistic regressions
approaches were shown for comparison purposes.
Results: In the final model, the following variables were associated with mortality or very poor HRQoL: age at
onset, cerebrovascular disease, diabetes, alcohol abuse, cancer, psychiatric disease, body mass index, Forced
Expiratory Volume (FEV1) % of predicted, atrial fibrillation, and prolonged QT time in ECG. The prediction accuracy
of the model was 77%, sensitivity 0.30, specificity 0.95, positive predictive value 0.68, negative predictive value 0.78,
and area under the ROC curve 0.69. While the sensitivity of the model reminded limited, good specificity, moderate
accuracy, comparable or better performance in classification and better performance in variable selection and data
usage in comparison to the logistic regression approaches, and positive and negative predictive values indicate that
the model has potential in predicting mortality and very poor HRQoL in COPD patients.
Conclusion: We developed a Bayesian prediction model which is potentially useful in predicting mortality and very
poor HRQoL in patients with COPD.
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Due to its ever increasing prevalence, chronic obstruc-
tive pulmonary disease (COPD) has become a global
health priority and a significant burden on the health
care system. With worldwide prevalence of 8–20%, de-
pending on which definition is used [1], it has been esti-
mated that COPD will be the third leading cause of
death by 2020 [2]. The principal goals of management of
COPD are to reduce symptoms, prevent exacerbations,
and maintain the patient’s physical and emotional cap-
abilities, and thereby improve the patient’s health-related
quality of life (HRQoL).
Assessment of HRQoL could be an important tool
in the management and monitoring of COPD due to
chronic, non-curable, and usually progressive nature of
the disease. So far, there is no single ‘state-of-the-art’ ap-
proach. We have previously validated two questionnaires
on COPD: the disease-specific AQ20 focusing solely on
respiratory health and 15D which has a generic approach
[3,4]. We found that the compliance rates and measure-
ment properties of both questionnaires were to a large
extent comparable and thus, either of them could easily
be used in clinical practice to monitor potential progres-
sion of the disease.
In clinical trials, the underlying diseases are often ex-
cluded, the severity staging of COPD is often limited,
and female patients under represented. In real world,
however, the severity of COPD varies considerably, sev-
eral phenotypes are recognized [5], and COPD is often
associated with a wide variety of co-morbidities which
might be of extreme importance for the patient’s well-
being and prognosis [6]. There is growing evidence that
the disease phenotype differs between genders [7-11]
and women often report lower HRQoL than men [12].
Several recently published articles have concentra-
ted on predictive factors of COPD mortality [13-16], or
hospitalization [17], or both [18]. Tsimogianni et al.
(2009) [19] studied predictive factors for length of stay
in a hospital and 3-year mortality. The following factors
have been found to be associated with mortality risk:
St George’s respiratory questionnaire total score, the
mental and physical components of the SF-36 HRQoL
scale [13], depressive symptoms [14], smoking [15], co-
morbidity [15], age and inspiratory capacity [16] and
PaO2 [15,16], low forced expiratory volume in 1 s (FEV1)
[16], and increased body mass index [16,19]. Older age,
FEV1% of predicted, emergency room visits for COPD
during the previous year, cardiovascular co-morbidity,
and prednisone use at the baseline were associated with
a greater risk of hospitalization [17]. Scoring on the
Medical Research Council chronic dyspnea scale has
been proved to be predictive of length of stay in a hos-
pital [19]. These predictions have mostly been made
using regression methods.Recently, Himes et al. (2009) [20] used Bayesian mo-
dels to predict the development of COPD in asthma
patients, finding age, sex, ethnic background, smoking
history, and eight co-morbidities to predict the develop-
ment of COPD. The prediction accuracy was excellent:
the area under the ROC curve was 0.83. The strongest
predictor of COPD was age.
The aim of this study was to develop a naïve Bayesian
classification (NBC) merger model (NBCMM) by which
we could identify the risk factors for mortality and
very poor HRQoL in a large real world COPD patient
cohort. We included to the model the most essential
lung function measurements, patients’ health behavior,
and common co-existing chronic diseases in the pa-
tient profile.
Methods
Subjects
Hospital Discharge Registries were used to identify all
patients with COPD who had visited the Pulmonary
Clinics of the Helsinki and Turku University Hospitals
(some 700 000 inhabitants live in the area) during the
years 1995–2006. The databases were screened by
ICD10 code J44.8 and contained all patients between 18
to 75 years of age. All identified patients were invited to
the study without further selection. The recruitment was
done through a two-phase mailing campaign, through
which altogether 844 patients participated to the study.
The overall response rate was 27%. The research visits
occurred during the years 2005–2007. All the partici-
pants gave their informed consent which allowed the re-
search consortium to collect, merge, and analyze their
comprehensive medical history from all the healthcare
providers who had treated them during the past 5–10
years and agreed to continue their follow-up on an an-
nual basis for the next 10 years.
All the hospitals, health care centres, and other out-
patient clinics that had treated the patients were con-
tacted to archive a complete, unbroken medical history
for each participant. The patients’ social security number
was used to combine the data from different sources.
Source data with personal identifiers was managed and
stored in the Clinical Research Centres administered by
the Helsinki and Turku University Central Hospitals.
From the medical records we identified the results of
flow-volume spirometry including bronchodilatation tests,
weight and height, ECGs at rest, and smoking status of
the patient, and arterial blood gas analysis results. The
most up-to-date results were used in the analysis. The ref-
erence values for FEV1 (forced expiratory volume in 1 sec-
ond) and FVC (forced vital capacity) used in Finnish
clinical practice are validated in large Finnish population
samples consisted of both genders and a wide range of age
group [21]. All the given diagnoses stated in the medical
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of onset and certainty of the diagnosis was determined.
In the data, category ‘coronary disease’ included the
patients who have had a myocardial infarct, acute coro-
nary syndrome, or angina pectoris diagnosed by an in-
ternist. ‘Cerebrovascular diseases’ included patients with
strokes and transient ischemic attacks diagnosed by a
neurologist. ‘Cardiovascular diseases’ consisted of pa-
tients having one of the following diseases: coronary,
cerebrovascular disease, or peripheral artery occlusive
disease. Category ‘diabetes’ includes patients with the
type 1 and 2 disease. Chronic alcoholism, alcohol use
disorder, and treatment of an alcohol use related dis-
order were all categorized as ‘alcohol abuse’. A wide
range of psychotic disorders and long lasting clinical de-
pression and anxiety with a need for regular medication
were categorized as ‘psychiatric disease’. Category ‘can-
cer’ included all malignant solid tumors and malignant
haematological diseases. Annual deaths were determined
from the national population registry.
The study approach was approved by the Coordinating
Ethics Committee of the Helsinki and Uusimaa Hospital
District and permission to conduct this research was
granted by the Helsinki and Turku University Hospitals.Assessment of HRQoL and clinical measures
HRQoL was assessed using the self-administered generic
15D instrument [3]. All participants filled in during the
research visit without any guidance from the research
personnel. The 15D instrument can be used primarily as
a single index measure ranging from a minimum score
of 0 to a score of 1 for perfect health, but also as a pro-
file measure. It describes health status with mobility,
vision, hearing, breathing, sleeping, eating, speech, elim-
ination, usual activities, mental function, discomfort and
symptoms, depression, distress, vitality, and sexual activ-
ity. More generally, in most of the important properties
(reliability, validity, discriminatory power, and respon-
siveness) the 15D instrument compares at least equally
with other commonly-used preference-based generic
HRQoL instruments such as EQ-5D, SF-6D, and HUI3
[3,22,23].
To categorize the patients as having either lower (very
poor) or higher (typical) HRQoL, we used as the cut
off –point one standard deviation under the mean of the
total score. Thus, patients with the total score ≤ 0.70
(N=175, 27%) in 15D were determined as having very
poor HRQoL. In a Finnish study using 15D in conse-
cutive patients in secondary care, 15D index 0.70 was
the mean result of patients who reported their general
health as "very poor" [24]. Rest of the patients formed
the group of typical HRQoL. In mortality model, all
cause deaths were analysed as the end point.Bayesian classification
PREQ, a web-based NBC, was used in the modeling.
PREQ is a Bayesian classifier which is able to use multi-
dimensional priors, e.g. separate priors for the outcome
variable in general and for the outcome variable accor-
ding to each predicting variable. NBCs have equaled
or outperformed logistic regressions, especially in small
data sets, in terms of prediction accuracy [25,26], vari-
able selection, and multiple performance measures [26].
Modeling of this data was done without informative a
priori information.
The precision of the model refers to its capability to
predict observations in the learning set precisely, and re-
liability refers to the model’s capability to predict obser-
vations in the test set or future data set which are not
included in model learning. There is a noted trade-off
between precision and reliability [26], and we searched
for a model with acceptable performance in both met-
rics. We assessed these with portioning [27], in which
the data set was divided into independent learning and
test sets.
In order to build a NBCMM with reasonable preci-
sion and reliability, we did 10 cross validation models
(portioning). In the first phase, we randomly divided
the material into a training set (n1 = 538) and a test set
(n2 = 200). This procedure was repeated nine times to
get 10 randomly created training sets and corresponding
test sets. Each training and test set contained one out-
come variable (HRQoL ≤ 0.70 or dead/living with
HRQoL > 0.70) and 49 potential predictive variables, be-
ing both numerical and categorical variables. Only base-
line variables have been used for prediction.
A Bayesian classification was performed for each train-
ing set and the created model was tested by using the
corresponding test set (i.e., the test were performed with
patients not used in the model building). Thus, we ob-
tained 10 different predictive models for a NBCMM mo-
del, each tested both internally using the teach set and
externally using the test set.
To select the most predictive variables, only those va-
riables present in at least four training set models (likely
variables) were accepted into the final model building.
After this procedure, we had a set with one outcome
variable and 18 potential predictive variables. These vari-
ables were used to create a final NBCMM. The validity
of this NBCMMwas assessed using common leave-one
-out cross-validation (LOOCV [24]).
We assessed the relationships between class variables
and predictors with posterior odds (PO), which equal
the product of the prior odds and the likelihood ratio,
and also estimated inversed probabilities, giving an idea
of the predictor’s strength. The POs were
PO ¼ PPC=PNPC
Table 1 Comparison of the demographic and clinical characteristics of the COPD patients with very poor or typical
HRQoL measured with the generic 15D instrument
Characteristics Very poor HRQoL N = 152 Typical HRQoL N = 587 P value
Male gender, N (%)1 93 (61.2) 377 (65.1) 0.4
Age, mean in years (±SD) 2 63.6 (7.0) 64.1 (6.8) 0.3
Duration of COPD, mean in years (±SD) 2 6.4 (4.3) 5.3 (5.0) 0.002
Age at asthma onset, mean in years (±SD) 2 52.8 (7.3) 57.6 (7.3) 0.002
Age at COPD onset, mean in years (±SD) 2 57.6 (7.6) 58.4 (7.3) 0.2
Pack years, mean (±SD) 2 49 (19) 51 (20) 0.4
DLcCOVA % of predicted, mean (±SD) 2 74 (23) 77 (22) 0.3
Baseline spirometry 2
FEV1% of predicted 52.5 (21.1) 58.4 (18.0) <0.0001
FVC% of predicted 68.1 (19.0) 76.2 (17.6) <0.0001
FEV1/FVC of predicted, mean (±SD) 61.6 (15.7) 61.5 (13.4) 0.7
Spirometry after bronchodilatation 2
FEV1% of predicted 57.7 (20.3) 61.7 (16.8) 0.04
FVC% of predicted 71.5 (17.9) 79.1 (16.9) <0.0001
FEV1/FVC of predicted, mean (±SD) 64.3 (14.8) 62.9 (13.2) 0.2
Proportion (%) of patients at GOLD 1
former stage 0: FEV1≥80% 11.2 9.5
stage 1: FEV1/FVC<70%, FEV1≥80% 1.0 3.0
stage 2: FEV1/FVC<70%, 50%≤FEV1<80% 24.5 40.4
stage 3: FEV1/FVC<70%, 30%≤FEV1<50% 18.4 18.0
stage 4: FEV1/FVC<70%, FEV1<30% 9.2 4.3
stage undefined: FEV1/FVC≥70%, FEV1<80% 35.7 24.8 0.02
Proportion (%) of patients with home oxygen therapy 8.6 1.7 <0.0001
In severe COPD (FEV1<50% of predicted)
2
Arterial O2 pressure, mean (±SD) 9.0 (1.5) 9.7 (14) 0.006
Arterial CO2 pressure, mean (±SD) 5.5 (0.9) 5.3 (0.5) 0.4
Proportion (%) of deaths during follow-up1 9.9 5.5 0.05
HRQL scores, mean (±SD) 2
Airway-specific (range 20–0) 13.0 (3.6) 6.9 (4.5) <0.0001
Generic (range 0–1) 0.63 (0.06) 0.83 (0.07) <0.0001
Proportion (%) of patients 1
Underweight BMI < 20 1.4 3.1
Normal weight BMI 20–25 33.6 41.2
Overweight BMI 25–30 53.6 50.1
Obese BMI > 30 11.4 5.6 0.04
Proportion (%) of patients with co-commitant 1
Coronary disease 27.0 20.2 0.07
Cerebrovascular disease 12.5 6.2 0.009
Cardiovascular disease 37.5 25.6 0.004
Diabetes 25.7 12.4 <0.0001
Peripheral artery occlusive disease 3.9 4.7 0.7
Metabolic syndrome 32.9 19.0 0.001
Alcohol abuse 21.7 13.3 0.01
Psychiatric condition 17.8 8.3 0.001
Hypertension 46.7 39.0 0.09
1Chi-square test, 2Mann-Whitney U test.
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the non-predicted class. POs are not directly dependent
on data size, and they give an idea of the predictor’s
strength [24]. The credibility intervals (CrI) for accur-
acies and POs were estimated using the Jeffreys interval
[26,27]. Specificity, sensitivity, positive predictive value,
negative predictive value, and area under the ROC curve
were also established.
In addition, the classification performance of obtained
NBCMM was compared to the classification perform-
ance of common logistic regression (logit) models. Six
logit models were implemented in Stata v10: Logit1 was
based on all variables included in the NBCMM (this
was comparable to the NBCMM in terms of includedTable 2 Predicting variables present in ten random sets and i
Variable Definition of variable
Gender male/female
Current smoking reported smoking yes/no
Year of onset of COPD numerical variable
Age at onset of COPD numerical variable
Age at onset of asthma numerical variable
Duration of COPD numerical variable
Hypertension diagnosed hypertension with medication
Cerebrovascular disease diagnosed cerebrovascular disease yes/n
Peripheral artery occlusive disease diagnosed peripheral artery occlusive dis
Any cardiovascular disease diagnosed any cardiovascular disease yes
Diabetes diagnosed diabetes yes/no
Metabolic syndrome diagnosed metabolic syndrome yes/no
Hypercholesterolemia diagnosed hypercholesterolemia with med
Hypothryreosis diagnosed hypothyreosis with medicatio
Alcoholism diagnosed alcoholism yes/no
Cancer diagnosed cancer yes/no
Atrial fibrillation diagnosed permanent atrial fibrillation ye
Psychiatric disease diagnosed any psychiatric disease yes/no
Body mass index 1. BMI < 20
2. BMI 20–25
3. BMI 25.1 – 30
4. BMI > 30
Body mass index change numerical variable
DLcCOVA % of predicted numerical variable
RV % of predicted numerical variable
FVC baseline % of predicted numerical variable
FEV1 at baseline % of predicted numerical variable
QRS axel in ECG numerical variable
QTc duration in ECG numerical variable
QRS duration in ECG numerical variablepredictors), logit2 was based on variables which had at
least 80% of observations present, logit3 was based on
variables which had 100% of observations present (this
was comparable to the NBCMM in terms of number
of observations included), logit4 is based on forward
stepwise elimination with p-value 0.10 threshold for the
predictors, logit5 is based on backward stepwise elimin-
ation with p-value 0.10 threshold for the predictors (this
shows how well the greedy hill-descending predictor se-
lection [26] and NBCMM approach performed in com-
parison to the p-value selection), and logit6 is based on
manual one-by-one dropping of the predictor variable
with the poorest p-value until all logit predictors have a
p-value below 0.10.n the final model
Model number
1 2 3 4 5 6 7 8 9 10 Final
✓ ✓ ✓ ✓
✓ ✓
✓ ✓ ✓
✓
✓ ✓
✓ ✓
yes/no ✓ ✓ ✓
o ✓ ✓ ✓ ✓ ✓ ✓ ✓
ease yes/no ✓
/no ✓ ✓ ✓ ✓
✓ ✓ ✓ ✓ ✓ ✓ ✓
✓ ✓ ✓ ✓
ication yes/no ✓ ✓
n yes/no ✓ ✓
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
s/no ✓ ✓ ✓ ✓ ✓ ✓ ✓
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
✓ ✓ ✓ ✓ ✓
✓ ✓ ✓ ✓
✓ ✓
✓ ✓
✓ ✓ ✓
✓ ✓ ✓ ✓ ✓
✓ ✓
✓ ✓ ✓ ✓ ✓ ✓ ✓
✓
Table 3 Diagnostic values of ten random training sets compared to corresponding test sets
Training set number Sensitivity Specificity Diagnostic accuracy Positive predictive value Negative predictive value
1 23.4 95.4 78.5 61.1 80.2
2 15.6 94.8 77.0 46.7 79.5
3 21.7 93.5 77.0 50 80
4 16.7 96.1 77.0 57.1 78.5
5 30.2 87.8 72.5 47.1 77.7
6 12.1 96.5 72.0 58.3 72.9
7 15.4 92.6 72.5 42.1 75.7
8 4.2 97.4 75.0 33.3 76.3
9 41.1 85.4 73.0 52.3 78.9
10 14.4 88.1 67.0 32 72
mean 19.5 92.8 74.2 48 77.2
standard deviation 10.3 4.2 3.4 9.9 2.9
Died or very poor
HRQoL
Diagnosed
cerebrovascular
disease
Diabetes
Alcohol abuse
Age at onset of
asthma
Cancer
FEV1 % of
predicted in
spirometry
Corrected QT-time
below 378 ms in
ECG
Any psychiatric
disease
Atrial fibrillation
Body mass
index
Figure 1 Final NBC model for predicting death or living with
very poor health-related quality of life.
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Patient recruitment and selection
A total of 844 patients participated in the study. The
COPD diagnosis was re-evaluated. This evaluation led
to the exclusion of 105 patients (explained in detail in
previous study) [28]. Thus, a final cohort of 739 eligible
patients with smoking-related symptomatic chronic bron-
chitis was included in the modeling. Based on their retro-
spective medical records, the clinical and demographic
findings of participants are shown in Table 1 on average
5.5 years prior to the evaluation of their HRQoL by using
the 15D instrument (Table 1). According to the GOLD
criteria, a majority of the patients belonged to stages 2–3,
i.e. moderate to severe COPD. So far the cohort has been
monitored 1–3 years. After the first follow-up year a total
of 49 patients (4.0%) had deceased.
The following demographic and clinical variables were
recorded: age, gender, duration of the disease, body mass
index (BMI), current smoking status, package years, results
of the baseline and post-bronchodilatation spirometry and
single breath diffusing capacity corrected by hemoglo-
bin concentration and alveolar volume (DLcCOVA), ECG
trace, and common co-existing diseases (Table 2). The pre-
dictors of very poor HRQoL (15D total score <0.70) were
assessed using the 15D instrument. We also studied the
clinical predictors of all cause death during the follow-up
period.
In the first phase we constructed prediction models by
using the randomly selected training sets. These models
were separately compared with the corresponding test
sets. The diagnostic values of ten random training sets
compared with the corresponding test sets are presented
in Table 3. The proportion of subjects having very poor
HRQoL or who died varied between 25.8% – 30.5%
(mean 28.7%). The diagnostic values of these models, de-
rived from the accuracy and predictive values, were at agood level, but the mean sensitivity of the model was
only 19.5%.
In the final model, the following variables were associ-
ated with mortality or very poor HRQoL: age at onset of
COPD, diagnosed cerebrovascular disease, diabetes, al-
cohol abuse, cancer, any psychiatric disease, body mass
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tion, and corrected QT time below 378 ms in ECG. The
final model is presented in graphical form in Figure 1.
Posterior distributions and inversed probabilities of
the final model using a NBC according to each predict-
ive variable are presented in Table 4. The results indicate
that patient age over 65 years at asthma onset, normal
body mass index, and FEV1 over 89 are strong factors
that protect against death or very poor HRQoL. Other
factors in the model are suggestive of a protective effect.
The same factors do not work as risk factors, as seen
when POs as protective factors are compared with
figures of risk factors in Table 4. The absence of co-
morbidity (diabetes, alcoholism, cancer, psychiatric dis-
ease, atrial fibrillation) is a strong protective factor against
death or very poor HRQoL. Thus, the model is good in
predicting health, but there is no good value for risk fac-
tors in predicting disease.
When the total material was fitted into the model,
the following results were achieved: prediction accuracy
77%, sensitivity 0.30, specificity 0.95, positive predictive
value 0.68, negative predictive value 0.78, and area under
the ROC 0.69. In LOOCV, the default classificationTable 4 Main results: posterior distributions and inversed pro
Factors of very poor QoL/death Predicted class
Protective Alive with not very poor Qo
% 95% CrI (%) PO
Age at asthma onset over 65.49 80.0 76.9 83.0 4.0
No CVD 77.0 73.6 80.1 3.3
No diabetes 76.0 72.6 79.2 3.2
No alcoholism 75.0 71.5 78.2 3.0
No cancer 74.0 70.6 77.3 2.8
No psychiatric disease 75.0 71.5 78.2 3.0
BMI 0 87.0 84.3 89.4 6.7
FEV1 over 89.61 81.0 77.8 83.9 4.3
No AF 74.0 70.6 77.3 2.8
QT below 378.17 71.0 67.4 74.3 2.4
Risk Very poor QoL/death
% 95% CrI (%) PO
Age at asthma onset below 45.53 47.0 43.2 50.8 0.9
CVD 37.0 33.3 40.7 0.6
Diabetes 43.0 39.2 46.8 0.8
Alcoholism 40.0 36.3 43.4 0.7
Cancer 49.0 45.2 52.8 1.0
Psychiatric disease 46.0 42.2 49.9 0.9
BMI 3 51.0 47.2 54.8 1.0
FEV1 below 31.11 50.0 46.2 53.9 1.0
AF 47.0 43.2 50.8 0.9
QT over 506.59 98.0 96.7 98.9 49.0 2score (best guess) was 72.0% (log-score 0.583) and the
model’s performance with selected variables was 75.4%
(corresponding log-score 0.536).
Table 5 shows the results of logit models. The logit1
with correspondent predictors to NBCMM had margin-
ally higher classification accuracy in comparison to the
NBCMM. However, the logit1 used only 56% of the 647
observations in the data set and may have classification
accuracy between 44–78% if all observations were mod-
eled. The logit2 had relatively similar classification ac-
curacy in comparison to the NBCMM. It used 85% of
the observations in the data set and may have classifica-
tion accuracy between 66-78% if all observations were
modeled. The logit3 with all observations used had lo-
wer classification accuracy (72%) in comparison to the
NBCMM.
The logit4 and logit5 (stepwise machine learned mo-
dels based on p-values) had marginally lower classifi-
cation accuracy (76%) in comparison to the NBCMM.
However, they used only 12% of the observations in the
data set, ignored many clinically meaningful predictors
and may have classification accuracy between 9–76%
if all observations were modeled. The logit 6 (manuallybabilities of the final NBCMM using a NBC
Evidence strength
L Inversed (If alive with not very poor QoL)
95% CrI % 95% CrI (%) PO 95% CrI
3.3 4.9 16.0 13.4 19.1 0.2 0.2 0.2
2.8 4.0 76.0 72.6 79.2 3.2 2.6 3.8
2.6 3.8 88.0 85.3 90.3 7.3 5.8 9.3
2.5 3.6 87.0 84.3 89.4 6.7 5.4 8.4
2.4 3.4 96.0 94.3 97.3 24.0 16.5 36.0
2.5 3.6 93.0 90.9 94.8 13.3 10.0 18.2
5.4 8.4 3.0 1.8 4.4 0.0 0.0 0.0
3.5 5.2 5.0 3.5 6.8 0.1 0.0 0.1
2.4 3.4 95.0 93.2 96.5 19.0 13.7 27.6
2.1 2.9 4.0 2.7 5.7 0.0 0.0 0.1
Inversed (If very poor QoL/death)
95% CrI % 95% CrI (%) PO 95% CrI
0.8 1.0 18.0 15.1 21.0 0.2 0.2 0.3
0.5 0.7 38.0 34.3 41.8 0.6 0.5 0.7
0.6 0.9 24.0 20.8 27.4 0.3 0.3 0.4
0.6 0.8 23.0 19.9 26.4 0.3 0.2 0.4
0.8 1.1 10.0 7.9 12.5 0.1 0.1 0.1
0.7 1.0 17.0 14.3 20.0 0.2 0.2 0.3
0.9 1.2 12.0 9.7 14.7 0.1 0.1 0.2
0.9 1.2 12.0 9.7 14.7 0.1 0.1 0.2
0.8 1.0 11.0 8.7 13.6 0.1 0.1 0.2
9.3 89.9 3.0 1.8 4.5 0.0 0.0 0.0
Table 5 Logistic regression models with six different approaches
Very poor HRQoL/
death outcome
Logit 1 Logit 2 Logit3 Logit 4 Logit5 Logit6
Parameter OR SE OR SE OR SE OR SE OR SE OR SE
Age at onset of COPD 0.9772 0.0178 0.9860 0.0148 0.8432* 0.0585 0.9342* 0.0273
Age at onset asthma 0.8469* 0.0560
Year of birth 0.8579 0.0680 0.8663 0.0647 0.9163* 0.0313
Diagnosed cerebrovascular
disease
2.2090 0.9669 2.4865* 0.8858 2.5121** 0.7810
Diabetes 2.0537* 0.6558 2.2233** 0.6105 2.2204** 0.5260
Alcohol abuse 2.1063* 0.6814 2.4580** 0.6461 1.9996** 0.4726 2.4388** 0.7556
Cancer 2.5036 1.3626 2.1930** 1.2808 2.5107* 0.8961
Any psychiatric disease 4.6815*** 1.7979 3.3283*** 1.0637 2.5081** 0.7054 3.3262 2.4100 4.0301 2.9826 3.8206*** 1.4034
Body mass index 1.2048 0.2493 1.4440* 0.2496
FEV1% of predicted spirometry 0.9761** 0.0071 1.4440*** 0.0580 0.9851* 0.0065
Atrial fibrillation 3.1544* 3.1544 2.6895* 1.1314
Corrected QT-time 1.0093* 0.0047
Tests Value p Value p Value p Value p Value p Value p
N included to the model 365 547 647 75 75 389
Probability of the model (chi2) 52.90 <0.0001 72.00 <0.0001 48.21 <0.0001 10.25 0.0166 10.28 0.0163 36.94 <0.0001
Pseudo R2 12.18% 11.69% 6.38% 12.07% 12.11% 7.88%
Sensitivity 33.01% 24.09% 15.43% 21.05% 21.05% 21.24%
Specificity 95.80% 95.61% 93.64% 94.64% 94.64% 94.20%
Positive predictive value 75.56% 64.71% 47.37% 57.14% 57.14% 60.00%
Negative predictive value 78.44% 79.03% 74.92% 77.94% 77.94% 74.50%
Log likelihood −190.73 −271.87 −353.57 −37.32 −37.31 −215.93
Akaike information criteria 403.46 561.74 719.14 82.65 82.61 445.87
Bayesian information criteria 446.36 600.48 745.98 91.92 91.88 473.61
Proportion of observations
used
56.41% 84.54% 100.00% 11.59% 11.59% 60.12%
Correct classification of used N 78.08% 77.70% 72.49% 76.00% 76.00% 73.01%
Worst possible correct
classification among all (N 647)
44.05% 65.69% 72.49% 8.81% 8.81% 43.89%
NBCMM = naïve Bayesian classification merger model. Logit1 = all variables included in the NBCMM (comparable to the NBCMM in terms of predictors included
to the logit model). Logit2 = variables which had at least 80% of observations present. Logit3 = variables which had 100% of observations present (comparable to
the NBCMM in terms of number of observations included). Logit4 = forward stepwise elimination with p-value 0.10 threshold. Logit5 = backward stepwise
elimination with p-value 0.10 threshold (shows how well the greedy hill-descending predictor selection of naïve Bayes approach performed in comparison to the
p-value selection). Logit6 = manual one-by-one dropping of the predictor variable with the poorest p-value until all logit predictors have a p-value below 0.10.
*p<0.050. **p<0.010. ***p<0.001.
Ryynänen et al. BMC Medical Informatics and Decision Making 2013, 13:34 Page 8 of 10
http://www.biomedcentral.com/1472-6947/13/34selected predictors based on the p-values) had lower clas-
sification accuracy (73%) in comparison to the NBCMM.
Yet, the logit6 used only 60% of the observations in
the data set and may have classification accuracy between
44–73% if all observations were modeled. The poorer per-
formance of p-value based variable selection for the logit
model (stepwise or manual selection) in comparison
to the greedy hill-descending algorithm of NBC may
result from the complex nature of the data set (e.g. cross-
censoring present in the variable values).
The sensitivity of the NBCMM was limited in this
case. However, good specificity, moderate predictionaccuracy, comparable or higher accuracy as well as more
efficient variable selection and data usage in comparison
to the logit model, and positive and negative predictive
values indicated that the model has potential in predicting
mortality and very poor HRQoL in COPD patients.
Discussion and conclusion
In this study we used a NBC to detect predictive factors
for very poor HRQoL and mortality in COPD patients.
HRQoL was measured with a 15D instrument. The out-
come variable was dichotomized to poor treatment out-
come, poor outcome being expressed as both mortality
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tion justified, because it is clinically important to distin-
guish patients with with very poor outcome.
The 15D instrument is highly valuated [29]. 15D total
scores have been demonstrated to be significantly lower
in COPD patients than in age-matched population [30].
The total 15D score has been proved to be significantly
correlated with SGRQ (St George's Respiratory Ques-
tionnaire), and the breathing subscale of 15D has been
significantly correlated with clinical symptoms and func-
tional parameters in COPD patients [31]. 15D scores
have been found to change in COPD patients receiving
pulmonary rehabilitation, indicating the usefulness of
HRQoL in evaluating COPD rehabilitation programs [32].
In the Finnish health care system, the medication pay-
ment compensation for COPD is available for patients
with FEV permanently less than 40% of the predicted or
permanently less than 50% if the have been at least two
exacerbation periods or other complications. The pay-
ment compensation makes that all patients with those
values have passed the same system. It also makes the
population constant.
We used a NBC for the analysis. Despite its simplicity,
its performance is comparable with conventional [26] or
more sophisticated methods [33]. In line with an earlier
study [26], NBC’s performance was shown here in com-
parison to different logit modeling approaches in terms
of correspondent or better accuracy and better variable
selection. NBCs can manage complicated and limited
data, they are easy to use for a clinician, and the results
are clearly visualized [26,33-36]. The predictive perform-
ance of NBCs can be improved considerably with in-
formative priors [26,37,38]. In these situations, the NBC’s
performance may even exceed the performance of logistic
regression methods [26,38].
Predicting results may be improved by two ways. Firstly,
adding prior information for the model may improve pre-
dictions especially in a situation when the model is applied
to a new environment. Secondly, finding new predic-
ting variables, for example genetic factors associated
with COPD, could be very useful in predicting the out-
come. We don't expect that a larger dataset could be very
helpful.
Our material consisted of patients derived from the
patient flow of pulmonary clinics in two large referral
hospitals. We consider that the results can be general-
ized to COPD patients in secondary care. This study was
limited to patients with COPD diagnosis. However, our
model is better for predicting health than for predicting
morbidity/mortality (very poor HRQoL/death).
Our results cannot be directly compared with previous
studies due to the different outcomes. Also, previous stu-
dies were performed by using logistic regression methods
to identify risk factors. However, co-morbidity, FEV1% ofpredicted, and increased BMI are common predictive
factors in our study and in the previous studies. Age
over 65 years at onset of the disease protected against
death or very poor HRQoL, which was a new finding.
This is probably due to milder disease with different
disease expansion.
There is a trend towards earlier diagnosis and more
active therapeutic interventions in the treatment of
COPD to prevent the development of disabling dis-
ease [39]. It has become obvious that in addition to
lung function measures new tools are needed in the
management and monitoring of COPD. The statistical
approach used in our study provides a potentially new op-
portunity to identify patients with poor prognosis.
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